|
|
 |
| Ad-hoc Announcement dated August 30, 2005 |
|
New bone cement contract, changes on the Board, capital increase
aap Implantate AG, a German medical technology company specialized in bone fracture healing, joint replacement, bone cements and biomaterials, is to become Biomet Deutschland GmbH’s new official bone cement sales partner. By signing a several-year sales contract the company can now ensure that it will be able to supply its customers on a long-term basis and will also largely offset the bone cement sales contract that Schering-Plough terminated in April by marketing the wide range of products made by Biomet Germany, a member of the Biomet Europe Group.
Uwe Ahrens, aap Implantate AG’s founder and longstanding CEO, is retiring from the Management Board on September 30, 2005 and will be proposed as a member of the Supervisory Board at the company’s Annual General Meeting in 2006. He will continue to advise the company on various projects. In the future, directors Oliver Bielenstein and Bruke Alemu will manage the company jointly.
In the weeks ahead, aap Implantate AG plans a capital increase of up to 10%. The company intends to use the funds raised by the capital increase to finance a smaller-scale acquisition in the biomaterials segments in the second half and to continue to step up its operative business. Details of the capital increase will be announced shortly.
For further information, please contact:
| aap Implantate AG | | | Lorenzweg 5 | | | D-12099 Berlin | | | X | | | Oliver Bielenstein | Nanette Hüdepohl | | Director/CFO | Investor & Public Relations | Tel.: +49 30 75019 - 140 | Tel.: +49 30 75019 - 133 | Fax: +49 30 75019 - 290 | Fax: +49 30 75019 - 290 | | X | | | WKN 506660, ISIN DE0005066609 | | | Prime Standard/Regulated Market | | | Traded at all German Stock Exchanges |
|
|
|
|
|
Print this page
